Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The value of adding cisplatin, fluorouracil, and docetaxel (TPF) induction chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma is unclear. We aimed to compare TPF induction chemotherapy plus concurrent chemoradiotherapy with concurrent chemoradiotherapy alone in a suitably powered trial.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Oncol.

Title: The Lancet. Oncology

Publisher: Elsevier BV

ISSN (Electronic): 1474-5488

ISSN (Print): 1470-2045

Publication date (Electronic): Nov 2016

Volume: 17

Issue: 11

Affiliations

[1 ] Department of Radiation Oncology, Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou, China.

[2 ] Department of Radiation Oncology, Cancer Centre, West China Hospital, Sichuan University, Chengdu, China.

[3 ] Department of Radiation Oncology, The First People's Hospital of Foshan, Foshan, China.

[4 ] Department of Oncology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.

[5 ] Department of Radiation Oncology, Peking University School of Oncology, Beijing, China.

[6 ] Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China.

[7 ] Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, China.

[8 ] Department of Radiation Oncology, Cancer Hospital of Guangxi Medical University, Nanning, China.

[9 ] Department of Radiation Oncology, Fudan University Shanghai Cancer Centre, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.

[10 ] Department of Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, China.

[11 ] Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou, China.

[12 ] Clinical Trials Centre, Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou, China.

[13 ] Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China.

[14 ] Department of Radiation Oncology, Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou, China. Electronic address: majun2@mail.sysu.edu.cn.

Article

Publisher Item ID: S1470-2045(16)30410-7

DOI: 10.1016/S1470-2045(16)30410-7

PubMed ID: 27686945

SO-VID: 4de02f12-10bf-4641-926c-7807a86c8a8e

History

Data availability:

Comments

Comment on this article

scite_

Cited by 378

See all cited by

- Version 1